The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects by Fabio Coppedè
REVIEW
published: 25 June 2015
doi: 10.3389/fgene.2015.00223
Frontiers in Genetics | www.frontiersin.org 1 June 2015 | Volume 6 | Article 223
Edited by:
Wendy Robinson,
University of British Columbia, Canada
Reviewed by:
Angela Devlin,
Unversity of British Columbia, Canada
Stephanie Sherman,
Emory University, USA
*Correspondence:
Fabio Coppedè,
Section of Medical Genetics,
Department of Translational Research
and New Technologies in Medicine
and Surgery, Medical Genetics,
Medical School, University of Pisa, Via
Roma 55, 56126 Pisa, Italy
fabio.coppede@med.unipi.it
Specialty section:
This article was submitted to
Epigenomics and Epigenetics,
a section of the journal
Frontiers in Genetics
Received: 24 April 2015
Accepted: 10 June 2015
Published: 25 June 2015
Citation:
Coppedè F (2015) The genetics of
folate metabolism and maternal risk of
birth of a child with Down syndrome
and associated congenital heart
defects. Front. Genet. 6:223.
doi: 10.3389/fgene.2015.00223
The genetics of folate metabolism
and maternal risk of birth of a child
with Down syndrome and associated
congenital heart defects
Fabio Coppedè1, 2*
1 Section of Medical Genetics, Department of Translational Research and New Technologies in Medicine and Surgery,
University of Pisa, Pisa, Italy, 2 Interdepartmental Research Center Nutrafood “Nutraceuticals and Food for Health,” University
of Pisa, Pisa, Italy
Almost 15 years ago it was hypothesized that polymorphisms of genes encoding
enzymes involved in folate metabolism could lead to aberrant methylation of
peri-centromeric regions of chromosome 21, favoring its abnormal segregation during
maternal meiosis. Subsequently, more than 50 small case-control studies investigated
whether or not maternal polymorphisms of folate pathway genes could be risk factors
for the birth of a child with Down syndrome (DS), yielding conflicting and inconclusive
results. However, recent meta-analyses of those studies suggest that at least three of
those polymorphisms, namely MTHFR 677C>T, MTRR 66A>G, and RFC1 80G>A, are
likely to act as maternal risk factors for the birth of a child with trisomy 21, revealing
also complex gene-nutrient interactions. A large-cohort study also revealed that lack
of maternal folic acid supplementation at peri-conception resulted in increased risk for
a DS birth due to errors occurred at maternal meiosis II in the aging oocyte, and it
was shown that the methylation status of chromosome 21 peri-centromeric regions
could favor recombination errors during meiosis leading to its malsegregation. In this
regard, two recent case-control studies revealed association of maternal polymorphisms
or haplotypes of the DNMT3B gene, coding for an enzyme required for the regulation of
DNA methylation at centromeric and peri-centromeric regions of human chromosomes,
with risk of having a birth with DS. Furthermore, congenital heart defects (CHD) are found
in almost a half of DS births, and increasing evidence points to a possible contribution of
lack of folic acid supplementation at peri-conception, maternal polymorphisms of folate
pathway genes, and resulting epigenetic modifications of several genes, at the basis of
their occurrence. This review summarizes available case-control studies and literature
meta-analyses in order to provide a critical and up to date overview of what we currently
know in this field.
Keywords: folate, polymorphisms, Down syndrome, congenital heart defects, DNA methylation, epigenetics,
MTHFR, folic acid supplementation
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Introduction
Two studies conducted nearly 15 years ago in North America
(James et al., 1999; Hobbs et al., 2000) have suggested that
polymorphisms of genes encoding enzymes involved in the
folate metabolic pathway, also known as one-carbon metabolism,
may be maternal risk factors for the birth of a child with
Down syndrome (DS). In particular, it was hypothesized that
an altered metabolism of folate, resulting from the presence
of polymorphisms in metabolic genes, could lead to aberrant
methylation of peri-centromeric regions of chromosome 21,
favoring its abnormal segregation during maternal meiosis and
leading to the formation of eggs with two copies of chromosome
21, which, if fertilized, would result in a zygote with full trisomy
for chromosome 21 (James et al., 1999; Hobbs et al., 2000).
Those works were followed by more than 50 small case-control
studies all aimed to address this issue, listed in Table 1. Overall,
most of those papers are in favor of a possible contribution of
polymorphisms in folate-related genes as maternal risk factors
for the birth of a child with DS, however, they are often
conﬂicting and limited by the small sample size of case-control
cohorts (Table 1). In 2009, I reviewed the literature in the ﬁeld,
concluding that at that time no single gene could be clearly
linked to the maternal risk of birth of a child with DS, due
to the relatively small sample-size and the conﬂicting nature
of the ﬁndings among the diﬀerent studies (Coppedè, 2009). I
also recommended collaboration among research groups and/or
literature meta-analyses in order to increase the power to detect
association (Coppedè, 2009). Many papers have been produced
between 2009 and present days (Table 1), and literature meta-
analyses are nowadays available overall suggesting that at least
three polymorphisms of folate pathway genes are likely to be
associated to the maternal risk for trisomy 21 (Table 2), while an
increasing number of studies also suggest complex gene-gene and
gene-nutrient interactions (Tables 1, 3). However, the original
hypothesis linking impaired folate metabolism and abnormal
methylation levels of chromosome 21 peri-centromeric regions
(James et al., 1999) has not yet been demonstrated, even if in vitro
studies revealed that cells under folate deprivation increase the
rate of chromosome 21 aneuploidy (Wang et al., 2004; Beetstra
et al., 2005), and recent evidence suggests that DNA methylation
levels of peri-centromeric regions of chromosome 21 might be
responsible of recombination errors leading to its malsegregation
during meiosis (Oliver et al., 2014). Moreover, that hypothesis
(James et al., 1999) has been revised and implemented over
the years, leading researchers to hypothesize that maternal
polymorphisms of genes involved in folate metabolism could not
only favor chromosome 21malsegregation but, when transmitted
to a DS embryo, could also account for the probability that
it will survive up to the birth (Martínez-Frías et al., 2006),
or contribute to the onset of congenital defects (Brandalize
et al., 2009; Locke et al., 2010), such as congenital heart
defects (CHD) (Table 4). This article summarizes both case-
control studies and literature meta-analyses in order to provide
a critical and up to date review of what we currently know
about maternal polymorphisms of folate-related genes and risk
of birth of a child with DS and associated CHD, highlighting the
strengths and the limitations of our current knowledge in this
ﬁeld.
Methods
Major online databases, namely PubMed, Scopus, and Web
of Science, were searched up to April 24, 2015 using the
following terms: “folate,” “polymorphisms,” “gene variant,”
“genetic variant,” “homocysteine,” “congenital heart defects,”
and “Down syndrome.” Only peer-reviewed case-control studies
showing demographic data of case and control mothers, and
tabular data of allele and genotype frequencies, have been
considered for this review and included in Tables 1, 3, 4.
For articles not written in English, only those published in
peer-reviewed journals with an English written abstract clearly
showing all the relevant information were included. Meeting
abstracts, case-reports, commentaries, academic theses, letters
to the editors and review articles with no novel data, were not
included. All the available meta-analyses matching the search
criteria are included and listed in Table 2, providing that they
were written in English language with a clear indication of
inclusion and exclusion criteria, as well as available tabular data
showing both overall and subgroup analyses.
Folate Metabolism: an Overview
Folate is the general term for a water-soluble B vitamin (vitamin
B9) which is naturally found in foods such as green leafy
vegetables, liver, beans, egg yolks, cereals, some citric fruits, kiwis,
and strawberries (Fenech, 2012). Dietary folates are essential
for normal cell growth and replication, since they work as
donors and acceptors of one-carbon units during the synthesis
of nucleic acids, amino acids, and S-adenosylmethionine (SAM),
the main intracellular methylating agent (Figure 1). Therefore,
a folate restriction results in aberrant cell growth, impaired
DNA methylation, and increases the rate of point mutations,
chromosome damage, and aneuploidy (Wang et al., 2004;
Beetstra et al., 2005; Fenech, 2012). Folic acid is a synthetic
compound, structurally similar but with higher bioavailability
than naturally occurring folate, which is used in supplements
and in fortiﬁed foods (Barua et al., 2014). An overview of folate
metabolism, also known as one-carbon metabolism, is provided
in Figure 1 that illustrates the main enzymes of the pathway
whose gene polymorphisms have been investigated as potential
maternal risk factors for the birth of a child with DS.
5-Methyltetrahydrofolate (5-methylTHF) is the main form
of circulating folate in the plasma and can be transported into
the cells by means of folate carriers and receptors, one the best
characterized being the ubiquitously expressed reduced folate
carrier (RFC), coded by the SLC19A1 gene (commonly known
as RFC1 gene) (Hou and Matherly, 2014).
Intracellularly, 5-methylTHF functions as a methyl donor
for homocysteine (hcy) remethylation, a reaction catalyzed by
the methionine synthase (MTR) enzyme that transfers a methyl
group from 5-methylTHF to hcy, forming tetrahydrofolate
(THF) and methionine. Cobalamin (vitamin B12) is a cofactor
in this reaction and methionine synthase reductase (MTRR)
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TABLE 1 | Genetic association studies of folate pathway genes as maternal risk factors for having a child with Down syndrome.
References Country MDS/MCa Studied
polymorphism/s
Significant findings
James et al., 1999 USA
Canada
57/50 MTHFR 677C>T MTHFR 677CT (OR = 2.5; 95% CI = 1.0–5.7)
MTHFR 677CT + TT (OR = 2.6; 95% CI = 1.2–5.8)
Hobbs et al., 2000 USA
Canada
157/144 MTHFR 677C>T
MTRR 66A>G
MTHFR 677CT (OR = 1.9; 95% CI = 1.1–3.1)
MTHFR 677CT + TT (OR = 1.9; 95% CI = 1.2–3.0)
MTRR 66GG (OR = 2.6; 95% CI = 1.3–5.0)
MTRR 66AG + GG (OR = 1.8; 95% CI = 1.0–3.1)
MTHFR 677TT or CT + MTRR 66GG (OR = 4.1; 95% CI = 1.9–8.6)
O’Leary et al., 2002 Ireland 48/192 MTHFR 677C>T
MTRR 66A>G
MTRR 66AG (OR = 8.0; 95% CI = 1.0–61.2)
MTRR 66GG (OR = 15; 95% CI = 1.9–116)
MTRR 66AG + GG (OR = 10.5; 95% CI = 1.4–78.6)
MTHFR 677CT or TT + MTRR 66GG (OR = 3.0; 95% CI = 1.2–7.5)
Chadefaux-Vekemans et al.,
2002
France 85/107 MTHFR 677C>T No association observed
Grillo et al., 2002 Brazil 36/200 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677CT + MTHFR 1298AC
associated with increased maternal risk OR = N.A.
Stuppia et al., 2002 Italy 64/112 MTHFR 677C>T No association observed
Bosco et al., 2003 Italy 63/72 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTR 2756A>G
MTR 2756AG + GG (OR = 3.5; 95% CI = 1.2–10.9)
MTR 2756AG + MTRR 66AG (OR = 5.0; 95% CI = 1.1–24.1)
Takamura et al., 2004 Japan 31/60 MTHFR 677C>T No association observed
Bodurog˘lu et al., 2004 Turkey 152/91 MTHFR 677C>T
MTHFR 1298A>C
No association observed
da Silva et al., 2005 Brazil 154/158 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTR 2756A>G
CBS 844 ins68
MTHFR 677T allele (OR = 1.4; 95% CI = 1.0–2.1)
The presence of increasing numbers of the variant alleles (MTHFR 677T, MTHFR
1298C, MTR 2756G, MTRR 66G, and CBS 844ins68) increases maternal risk
(OR = 1.2; 95 CI = 1.0–1.6)
Chango et al., 2005 France 119/119 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTR 2756A>G
CBS 844 ins68
RFC1 80G>A
No association observed
Acácio et al., 2005 Brazil 70/88 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677CT + MTHFR 1298AC (OR = 5.7; 95% CI = 1.7–18.8)
Coppedè et al., 2006 Italy 80/111 MTHFR 677C>T
MTHFR 1298A>C
RFC1 80G>A
MTHFR 677TT + RFC1 80GG (OR = 6.0; 95% CI = 1.0–35.9)
MTHFR 1298AA + RFC1 80GA/AA (OR = 0.4; 95% CI = 0.1–0.9)
Rai et al., 2006 India 149/165 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677TT (OR = 7.7; 95% CI = 1.7–35.1)
MTHFR 1298CC (OR = 4.4; 95% CI = 1.4–13.3)
MTHFR 677CC + MTHFR 1298CC (OR = 4.1; 95% CI = 1.2–13.7)
Scala et al., 2006 Italy 94/264 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTHFR 1298C allele (OR = 1.5; 95% CI = 1.0–2.1)
RFC1 80G allele (OR = 1.5; 95% CI = 1.0–2.1)
MTHFR 1298CC (OR = 2.3; 95% CI = 1.1–5.0)
(Continued)
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TABLE 1 | Continued
References Country MDS/MCa Studied
polymorphism/s
Significant findings
MTR 2756A>G
CBS 844 ins68
RFC1 80G>A
MTHFD1 1958G>A
RFC1 80GG (OR = 2.0; 95% CI =1.0−4.1)
MTHFR 677TT + MTHFR 1298CC or CA (OR = 7.2; 95% CI= 1.4–47.2)
MTHFR 1298CC or CA + RFC1 80GG or GA (OR = 2.6; 95% CI =1.1–6.3)
RFC1 80GG + MTHFD1 1958AA (OR = 4.4; 95% CI = 1.2–17.9)
Wang et al., 2007 China 100/100 MTHFR 677C>T MTHFR 677CT (OR = 2.1; 95% CI = 1.1–3.9)
MTHFR 677TT (OR = 3.4; 95% CI = 1.4–8.4)
Meguid et al., 2008 Egypt 42/48 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677CT +TT (OR = 4.1; 95% CI = 1.0–5.7)
MTHFR 1298CC (OR = 31.5; 95% CI = 3.5–282.)
Martínez-Frías, 2008 Spain 146/188 MTHFR 677C>T
MTHFR 1298A>C
No association observed
Wang et al., 2008 China 64/70 MTHFR 677C>T
MTRR 66A>G
MTHFR 677TT (OR = 9.3; 95% CI = 2.9–29.7)
MTRR 66GG (OR = 5.2; 95% CI = 1.9–14.2)
MTHFR 677TT/CT + MTRR 66GG (OR = 6.0; 95% CI =2.0–17.5)
Biselli et al., 2008a Brazil 67/113 RFC1 80G>A
TCN2 776C>G
No association observed
Biselli et al., 2008b Brazil 72/194 MTHFR 677C>T
MTHFR 1298A>C
MTR 2756A>G
RFC1 80G>A
The presence of increasing numbers of 3 or more polymorphic alleles
among MTHFR 677T, MTHFR 1298C, MTR 2756G, and RFC1 80G,
increases maternal risk
(OR = 1.7; 95% CI = 1.0–3.0)
Kohli et al., 2008 India 104/109 MTHFR 677C>T No association observed
Santos-Rebouças et al.,
2008
Brazil 103/108 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
No association observed
Coppedè et al., 2009 Italy 94/113 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTR 2756A>G
TYMS 28bp 2R/3R
TYMS 1494 ins/del
MTHFR 677TT + MTR 2756AA (OR = 3.0; 95% CI = 1.0–8.5)
MTHFR 1298AC + TYMS 2R/2R (OR = 0.11; 95% CI = 0.1–0.5)
Pozzi et al., 2009 Italy 74/184 MTHFR 677C>T
MTRR 66A>G
MTRR 66AG (OR = 2.6; 95% CI = 1.2–5.5)
MTRR 66AG + GG (OR = 2.2; 95% CI = 1.1–4.4)
Fintelman-Rodrigues et al.,
2009
Brazil 114/110 RFC1 80G>A
TCN2 776C>G
MTR 2756A>G
CBS 844 ins68
MTR 2756AG/TCN2 776CC (OR = 3.2; 95% CI = 1.1–9.0)
Cyril et al., 2009 India 36/60 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677 (CT+TT) (OR = 12.6; 95% CI = 6.5–99.7)
Kokotas et al., 2009 Denmark 181/1084 MTHFR 677C>T No association observed
Brandalize et al., 2009 Brazil 239/197 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677CT or TT/MTHFR 1298AA (OR = 1.9; 95% CI = 1.1–3.5)
Brandalize et al., 2010 Brazil 239/197 MTR 2756A>G
MTRR 66A>G
RFC1 80G>A
CBS 844 ins68
Combined genotypes among MTR 2756A>G, MTRR 66A>G, CBS
844ins68, and RFC1 80G>A polymorphisms increase maternal risk. ORs
ranging from 4.8 to 6.9 depending on the number of risk alleles considered.
MTHFR 677T(from Brandalize et al., 2009) + MTRR 66G (OR = 1.5; 95% CI
= 1.0–2.3)
(Continued)
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TABLE 1 | Continued
References Country MDS/MCa Studied
polymorphism/s
Significant findings
Liao et al., 2010 China 60/68 MTHFR 677C>T
MTRR 66A>G
MTR 2756A>G
RFC1 80G>A
MTHFR 677TT (OR = 3.5; 95% CI = 1.3–9.5)
MTRR 66GG (OR = 3.2; 95% CI = 1.2–8.3)
MTHFR 677 (CT or TT) + MTRR 66GG (OR 9.5; 95% CI = 2.1–46.3)
MTHFR (CT or TT) + RFC-1 AA (OR 5.2; 95% CI = 1.7–15.9)
MTHFR 677CC + MTR 2756(AG or GG) (OR = 6.7; 95% CI = 1.2–35.0)
MTHFR 677 (CT or TT) + MTR 2756 AA (OR = 4.2; 95% CI = 1.5–11.6)
MTRR 66GG + MTR 2756AA (OR = 3.0; 95% CI = 1.1–8.7)
RFC1 80AA + MTR 2756AA (OR = 2.7; 95% CI = 1.2–6.5)
Neagos et al., 2010a Romania 26/46 RFC1 80G>A No association observed
Mendes et al., 2010 Brazil 105/184 DHFR 19 bp ins/del No association observed
Neagos et al., 2010b Romania 26/46 MTHFD1 1958G>A No association observed
Coppedè et al., 2010 Italy 29/32 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
MTR 2756A>G
RFC1 80G>A
TYMS 28 bp 2R/3R
TYMS 1494 ins/del
Artificial neural networks selected 6 variables (micronucleus frequency,
MTHFR 677TT, RFC1 80AA, TYMS 1494 6bp +/+, TYMS 28 bp 3R/3R and
MTR 2756AA genotypes) that allowed to discriminate between MDS and
control mothers with 90% accuracy
Vranekovic´ et al., 2010 Croatia 111/141 MTHFR 677C>T
MTHFR 1298A>C
No association observed
Sadiq et al., 2011 Jordan 53/29 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677T allele (OR 3.1; 95% CI = 1.3–7.7)
Marucci et al., 2012 Brazil 105/185 SHMT 1420C>T SHMT 1420CC (OR = 0.35; 95% CI = 0.2–0.6)
SHMT 1420CT (OR = 0.2; 95 % CI = 0.1–0.4)
Zampieri et al., 2012a Brazil 86/161 MTHFD1 1958G>A
BHMT 742A>G
BHMT 742AA (OR = 0.3; 95% CI = 0.1–0.9)
BHMT 742 (GA + AA) (OR = 0.6; 95% CI = 0.4–0.9)
Zampieri et al., 2012b Brazil 105/185 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 1317T>C
MTR 2756A>G
MTRR 66A>G
RFC1 80G>A
TCN2 67A>G
TCN2 776C>G
CBS 844ins68
CBS 833T>C
MTHFD1 1958G>A
BHMT 742G>A
MTHFR 677CT or TT (OR = 1.8; 95% CI = 1.0–3.1)
TCN2 776GG (OR = 2.4; 95% CI = 1.0–5.8)
BHMT 742AA (OR = 0.3; 95% CI = 0.1–0.8)
MTHFR 677C/1298A/1317T haplotype
(more frequent in control mothers P = 0.01)
Mohanty et al., 2012 India 52/52 MTHFR 677C>T No association observed
Tayeb, 2012 Saudi Arabia 30/40 MTHFR 677C>T No association observed
Wang et al., 2013a China 104/184 MTRR 524C>T MTRR 524TT (OR = 0.3; 95% CI = 0.1–0.9)
MTRR 524 (CT + TT) (OR = 0.6; 95% CI = 0.4–1.0)
Wang et al., 2013b China 104/184 RFC1 80G>A
CBS 833T>C
RFC1 80G allele (OR 1.5; 95% CI = 1.0–2.2)
CBS 833C (OR 1.5; 95% CI = 1.1–2.2)
RFC1 80GG + CBS 833TC (OR 4.8; 95% CI = 1.8–12.7)
(Continued)
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TABLE 1 | Continued
References Country MDS/MCa Studied
polymorphism/s
Significant findings
Amorim et al., 2013 Brazil 94/134 BHMT 742G>A BHMT 742A (OR = 0.6; 95% CI = 0.4–0.9)
BHMT 742AA (OR = 0.2; 95% CI = 0.04–0.8)
Coppedè et al., 2013a Italy 286/305 MTR 2756A>G No association observed
Coppedè et al., 2013b Italy 172/157 DNMT3B −579G>T
DNMT3B −149C>T
DNMT3B −579T (OR 0.7; 95% CI = 0.5–0.9)
DNMT3B −579GT (OR 0.5; 95% CI = 0.3–0.9)
DNMT3B −579 (GT+TT) (OR 0.5; 95% CI = 0.3–0.9)
DNMT3B −579GT + DNMT3B −149CC (OR = 0.2; 95% CI = 0.1–0.6)
Kaur and Kaur, 2013 India 110/111 MTHFR 677C>T No association observed
Cretu et al., 2013 Romania 26/46 CBS 844ins68 No association observed
Pandey et al., 2013 India 80/100 MTHFR 677C>T
MTHFR 1298A>C
MTHFR 1298 (AC+CC) (OR= 3.1, 95% CI 1.6–5.8)
Liao et al., 2014 China 76/115 MTHFD1 1958G>A
TCN2 776C>G
MTHFR 677CT/TT + MTHFD1 1958AA/GA (OR = 3.1; 95% CI = 1.1–9.0)
TCN2 776CG + MTHFR 677TT (OR = 3.6; 95% CI = 1.3–10.3)
MTHFR data taken from Liao et al. (2010)
Coppedè et al., 2014 Italy 253/298 MTRR 66A>G MTR 2756AG + MTRR 66AG (OR 1.8; 95 % CI = 1.0–3.2)
MTR data taken from Coppedè et al. (2013a)
Jaiswal et al., 2015 India 150/172 DNMT3B -579G>T
DNMT3B -149C>T
Significant increased frequency of the -579G/-149T haplotype in case
mothers
(P = 0.002)
Izci Ay et al., 2015 Turkey 47/49 MTHFR 677C>T
MTHFR 1298A>C
MTRR 66A>G
RFC1 80G>A
CBS 844ins68
MTHFD1 1958G>A
MTHFR 677C allele (OR = 0.5; 95% CI = 0.26–0.96)
MTHFD1 1958A allele (OR =1.9; 95% CI =1.1–3.3)
aMDS, mothers of Down syndrome individuals; MC, control mothers.
is required for the maintenance of MTR in its active state
(Guéant et al., 2013). TheMTR enzyme is ubiquitously expressed,
whereas another hcy remethylation system, mainly expressed in
the liver and in the kidneys, involves the betaine-homocysteine
methyltransferase (BHMT) enzyme (Obeid, 2013).
Methionine is then converted to SAM by methionine
adenosyltransferase, and most of the SAM generated is used
in transmethylation reactions whereby it is converted to S-
adenosylhomocysteine (SAH) by transferring the methyl group
to diverse biological acceptors, including proteins and DNA.
When the DNA is the ﬁnal acceptor of the methyl group, the
reaction is catalyzed by DNA methyltransferases (DNMTs). SAH
is then converted to hcy and adenosine by SAH hydrosylase
(Blom and Smulders, 2011). If not converted into methionine,
hcy can enter the transsulfuration pathway and be condensed
with serine to form cystathionine in a reaction catalyzed by
cystathionine β-synthase (CBS), which requires vitamin B6 as a
cofactor. Cystathionine is then hydrolyzed to cysteine that, apart
for its role in protein synthesis, is the precursor of the antioxidant
compound glutathione (GSH) (Blom and Smulders, 2011).
The folate pathway is also pivotal for the synthesis of nucleic
acid precursors, and THF, resulting from the reaction catalyzed
by MTR, can be directly converted into 5,10-methyleneTHF
by the action of serine hydroxymethyltransferase (SHMT).
Depending on cellular demands, 5,10-methyleneTHF can
be used for thymidylate synthesis, for purine synthesis,
or for the production of 5-methylTHF required for hcy
remethylation reactions (Figure 1). The tri-functional enzyme
methylenetetrahydrofolate dehydrogenase (MTHFD1)
interconverts THF derivatives for purine, methionine
and thymidylate synthesis. The enzyme consists of three
activities: 5,10-methylTHF dehydrogenase, 5,10-methenylTHF
cyclohydrolase, and 10-formylTHF synthetase, and catalyzes
three sequential reactions in the interconversion of THF
derivatives. Once generated by the 10-formylTHF synthetase
activity, 10-formylTHF can donate one-carbon groups for
purine biosynthesis. Thymidylate synthase (TYMS) converts
deoxyuridine monophosphate (dUMP) and 5,10-methyleneTHF
to deoxythymine monophosphate (dTMP) and dihydrofolate
(DHF) in the de novo synthesis of pyrimidines. DHF is then
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reduced back to THF by dihydrofolate reductase (DHFR)
(Coppedè, 2009). However, 5,10-methyleneTHF can also
be reduced to 5-methylTHF by methylenetetrahydrofolate
reductase (MTHFR), a vitamin B2 (riboﬂavin) dependent
enzyme, which is of great importance for the regulation of
available folate derivatives for homocysteine remethylation and
DNA methylation reactions (Martínez-Frías, 2008).
The one-carbon metabolic pathway is tightly regulated
by intracellular levels of metabolites and cofactors, such as
high intracellular SAM levels that activate CBS and inhibit
MTHFR, thus shifting hcy levels from transmethylation toward
transsulfuration reactions (Finkelstein, 2007). Cobalamin,
riboﬂavin, and vitamin B6 are required as cofactors of several
enzymes of the pathway (Figure 1), and their bioavailability
is essential for their function, such as for example in the case
of vitamin B12 which is a cofactor of MTR in the synthesis of
methionine (Guéant et al., 2013). Also cobalamin is obtained
from the diet, mainly from meat, eggs, and shellﬁsh, and the
absorbed cobalamin forms a complex with transcobalamin
(TC, formerly known as transcobalamin II) that transports the
vitamin from the bloodstream to the tissues, were cell surface
receptors allow it to enter the cells (Fedosov, 2012). The TCN2
gene codes for TC, and also TCN2 polymorphisms have been
investigated as potential maternal risk factors for the birth of a
DS child (Table 1).
The Biology of Human Female Meiosis, the
Origin of Chromosome 21 Malsegregation,
and the Potential Contribution of Dietary
Folate Availability
In females of the human species, primordial oocytes entermeiosis
I (MI) during fetal development, undergo DNA replication
and homologous recombination, and then remain arrested in
prophase I (dictyotene stage) for several years until ovulation.
Meiosis II (MII) is completed only after fertilization that can
occur from almost 13 to more than 40 years after the initiation
of meiosis I. Advanced maternal age at conception and impaired
chromosome 21 recombination represent the two best-known
maternal risk factors for chromosome 21 non-disjunction (Lamb
et al., 1997; Oliver et al., 2008). Particularly, MI errors are
associated with the absence of recombination or with the
presence of a single event near the telomere of 21q (Warren
et al., 1987; Lamb et al., 1997), and these associations appear
to be independent of the age of the oocyte (Oliver et al.,
2012). By contrast, MII errors are associated with recombination
occurring near the centromere of 21q (Lamb et al., 1997),
which appears to depend on the increasing age of the oocyte
(Oliver et al., 2012). In this regard it was recently observed
that genomic features that aﬀect the accessibility of a speciﬁc
chromosome region to recombination, including GC content
and CpG fraction, are altered in at least a proportion of
oocytes with MI and MII errors, and particularly in those with
recombinant events occurring in proximal regions, suggesting
that factors characteristic of peri-centromeric DNA such as
chromatin structure or epigenetic modiﬁcations may aﬀect the
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TABLE 4 | Genetic association studies of folate pathway genes as risk factors for having a child with Down syndrome and congenital heart defects.
References Country Cases Studied
polymorphism/s
Main findings
Brandalize et al., 2009 Brazil 239 MDSa:
90 of DS-CHDb
149 of DS without CHD
16 of DS with GI
diseasec
223 of DS without GI
disease
MTHFR 677C>T
MTHFR 1298A>C
MTHFR 677CT or TT increased the risk for CHD:
All MDS (OR = 2.07; 95% CI = 1.18–3.61),
non users of folic acid supplements: (OR = 2.26; 95% CI = 1.25–4.09),
users of folic acid supplements (OR = 1.07; 95% CI = 0.20–5.68).
No association of CHD with the MTHFR 1298A>C polymorphism.
No association of the studied polymorphisms with GI disease risk.
Locke et al., 2010 USA 121 case families:
(mother, father,
proband with DS-CHD)
122 control families:
(mother, father,
proband with DS and
no CHD)
45 single
nucleotide
polymorphisms
(SNPs) of:
MTHFR, MTR,
MTRR, RFC1, and
CBS
genes
Several RFC1 SNPs showed association with CHD (AVSDd): ORs
ranging from 1.3 to 3.8 depending on the model considered.
The MTHFR 1298A allele was over-transmitted to DS-AVSD individuals
and under-transmitted to those with no CHD.
Božovic´ et al., 2011 Croatia 112 DS individuals:
(54 DS-CHD and
58 DS without CHD)
221 healthy controls
107 MDS
34 triads:
(mother, father,
proband)
MTHFR 677C>T
MTHFR 1298A>C
No difference in allele or genotype frequencies between DS-CHD cases
and DS cases without CHD, no difference between DS cases and
controls, and no association between the presence of either MTHFR
677C>T or MTHFR 1298A>C polymorphisms in the mother and risk of
having a child with DS-CHD.
Elsayed et al., 2014 Egypt 61 mothers of CHD
individuals:
25 of DS-CHD
36 of CHD without DS
61 control mothers:
no children with DS or
CHD
MTHFR 677C>T Increased frequency of the MTHFR 677CT genotype in mothers of DS
individuals with atrioventricular canal compared to control mothers
(OR = 1.21; 95% CI = 1.02–1.43).
aMDS, mothers of Down syndrome individuals.
bDS-CHD, Down syndrome individuals with congenital heart defects.
cGI disease, congenital gastrointestinal disease.
dAVSD, atrioventricular septal defect.
accessibility of a speciﬁc chromosome region to recombination in
at least a proportion of oocytes with meiotic errors (Oliver et al.,
2014).
Interestingly, a recent screening of more than 20,000 oocytes
revealed that most of trisomy 21 cases are due to errors occurred
at maternal MI or to sequential MI and MII errors, and should
be therefore linked to recombination errors that occurred or
initiated during the fetal development of the mother in the
maternal grandmother’s body (Kuliev et al., 2011). However,
more than 35% of the cases were due to maternal MII errors,
occurring in adult life. In addition, not all trisomy 21 embryos
survive up to the birth, and the aneuploid embryo survival might
also depend on themeiotic origin of the error (Kuliev et al., 2011).
Despite that inadequate folate intake or impaired metabolism
can account for genomic features resulting in aberrant
chromosome 21 recombination and malsegregation (Fenech,
2012), we must take into account that, if it is the number and
location of the chiasmata between the chromosome 21 homologs
that predispose to either MI or MII errors, the predisposition
for most chromosome 21 meiotic errors may be set during the
prophase of the ﬁrst meiotic division, during the mother’s fetal
development in the maternal grandmother’s body (Lamb et al.,
1997; Coppedè, 2009; Oliver et al., 2012). Therefore, the maternal
risk for chromosome 21 malsegregation could be the result of a
complex gene-environment interaction involving the maternal
grandmother’s diet, lifestyles, and genotype and the maternal
genotype (Figure 2). Also the maternal diet at peri-conception,
that provides dietary folates for the completion of the meiotic
process, could be of relevance for chromosome 21malsegregation
(Figure 2). In this regard a recent population-based case-control
study compared the use of folic acid-containing supplements
among 702 mothers of infants with full trisomy 21 due to
maternal nondisjunction and 983 mothers of infants born with
no major birth defects. The study revealed that lack of folic
acid supplementation during pregnancy might be associated
speciﬁcally with MII errors in the aging oocyte (OR = 2.00; 95%
CI = 1.08–3.71) (Hollis et al., 2013). Indeed, the results of that
screening revealed that impaired maternal folate metabolism
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FIGURE 1 | Overview of the folate metabolic pathway. The
diagram illustrates the enzymes, metabolites and cofactors discussed
in this article. Enzymes: BHMT, betaine-homocysteine
methyltransferase; CBS, cystathionine β-synthase; DHFR, dihydrofolate
reductase; MTs, Methyltransferases; MTHFD1, methylenetetrahydrofolate
dehydrogenase; MTHFR, methylenetetrahydrofolate reductase; MTR,
methionine synthase; MTRR, methionine synthase reductase; RFC1,
reduced folate carrier; SHMT, serine hydroxymethyltransferase; TC,
transcobalamin; TCR, tanscobalamin receptor; TYMS, thymidilate
synthase. Metabolites: DHF, dihydrofolate; GSH, glutathione; THF,
tetrahydrofolate; dTMP, deoxythymidine monophosphate; dUMP,
deoxyuridine monophosphate; SAH, S-adenosyl homocysteine; SAM,
S-adenosylmethionine. Cofactors: B2, vitamin B2; B6, vitamin B6;
B12, vitamin B12 or cobalamin.
could be of relevance for the birth of a DS child at advanced
maternal age (Hollis et al., 2013).
Collectively, the above-discussed studies suggest that a clear
comprehension of the contribution of genetic polymorphisms
in folate-pathway genes to the maternal risk of birth of a child
with DS should take into account the origin of the meiotic
error and, possibly, the dietary habits and lifestyles of at least
two generations, i.e., the mother and the maternal grandmother
(Figure 2). Unfortunately, those data are largely missing from
the studies listed in Table 1, so that at present no meta-analysis
of those studies (Table 2) could stratify the data according to
MI or MII errors or to maternal age at conception. For what
instead concerns the maternal grandmother’s diet, only well
designed prospective studies will help us to understand if there
is a decreased risk for DS in the grandchildren of women taking
folic acid supplements.
Maternal Folate Metabolism and the Survival of a
Trisomic DS Embryo
For what instead concerns the possibility that a trisomic
DS embryo will survive up to the birth, a complex
maternal-embryonic interaction involving folate metabolism
was proposed (Martínez-Frías et al., 2006): Particularly, since
many genes involved in folate metabolism map to chromosome
21, including RFC1, CBS, and others, it was hypothesized that
embryos with full trisomy 21 might have a diﬀerent folate
demand than normal embryos, and that maternal folate intake
during pregnancy, maternal genotype for genes of the folate
metabolic pathway, as well as genotype and expression levels
of folate pathway genes mapping to chromosome 21 in the DS
embryo, could interact to determine death in utero or survival up
to the birth (Martínez-Frías et al., 2006) (Figure 2). This is a very
interesting hypothesis, but we lack data of comparison between
mothers of living DS individuals and women who experience loss
of trisomy 21 pregnancies in order to evaluate diﬀerences in the
frequency of polymorphisms of folate pathway genes between
the two groups, or the preferential transmission of certain
alleles to those DS embryos that reach the birth with respect
to those that die in utero, so that the question is still unsolved.
However, as discussed in the next sections of this paper, we
cannot exclude that maternal polymorphisms of folate pathway
genes, their preferential transmission to a DS embryo, as well as
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FIGURE 2 | Trans-generational contribution of folate metabolism to
the risk of birth of a child with Down syndrome. The maternal
grandmother’s diet during pregnancy provides dietary folates, i.e., the
one-carbon units required for the correct development of the mother which is
still a developing embryo in the maternal grandmother’s body, including
those required for the initiation of meiosis of primordial oocytes.
Chromosome 21 recombination errors, leading to either meiosis I (MI) or
meiosis II (MII) malsegregation events, occur during the prophase of the first
meiotic division of primordial maternal oocytes in the maternal grandmother’s
body. Therefore, the predisposition to those errors is likely to result from
complex interactions among the maternal grandmother’s dietary provision of
folate, her lifestyles such as smoking and drinking that can impair folate
metabolism, and both the grandmother’s genotype and the genotype of the
mother (i.e., the different alleles of folate pathway genes that can account for
inter-individual differences in folate absorption and metabolism). The
maternal diet and lifestyles at peri-conception and during pregnancy can
account for MII errors, as well as for the correct provision of dietary folates to
the developing embryo. In this regard, it was hypothesized that complex
interactions among maternal diet, lifestyles and genotype, and the metabolic
demands of fetuses with trisomy 21, that overexpress several folate pathway
genes mapping to chromosome 21, could account for either abortion or
survival up to the birth. Those complex gene-environment interactions can
also result in epigenetic changes in the developing embryo potentially
affecting the birth and/or the complexity of the phenotype.
epigenetic modiﬁcations and expression levels of folate-related
genes mapping to chromosome 21, could contribute to the DS
phenotype, including the development of congenital defects or
that of other diseases later in life.
Polymorphisms of Folate Pathway Genes
and Maternal Risk of Birth of a Child with
DS
Methylenetetrahydrofolate Reductase (MTHFR)
MTHFR catalyzes the reduction of 5,10-methyleneTHF to
5-methylTHF, which is required for the remethylation of
hcy to methionine (Figure 1). A common MTHFR 677C>T
polymorphism (rs1801133), resulting in Ala222Val amino acid
substitution, is known to reduce enzyme activity. Indeed,
MTHFR works as a dimer protein that is stabilized by
physiological levels of folate, and the MTHFR 677T allele
renders the enzyme thermolabile, particularly in homozygous
TT individuals that are prone to dimer destabilization under
conditions of reduced folate bioavailability (Guenther et al.,
1999; Martínez-Frías, 2008). As a result, the MTHFR 677TT
genotype has been often associated with hyperhomocysteinemia
(Martínez-Frías, 2008). In 1999, James and coworkers reported
increased plasma hcy levels and an increased frequency of both
MTHFR 677CT and TT genotypes in mothers of DS individuals
(MDS) with respect to control mothers, and that paper opened
the way to the study of folate gene polymorphisms as maternal
risk factors for the birth of a child with DS (James et al., 1999). To
date, the MTHFR 677C>T polymorphism has been investigated
in more than 30 small case-control studies as a potential maternal
risk factor for having a birth with DS, yielding conﬂicting
results (Table 1). The ﬁrst meta-analysis, performed in 2007 to
overcome the limits of small case-control cohorts, included 1.129
MDS and 1.489 control mothers, reported borderline results,
and could neither conﬁrm nor exclude a contribution for this
polymorphism (Zintzaras, 2007), but all the subsequent meta-
analyses, performed in recent years following the increasing
number of available research papers, conﬁrmed association
with the maternal risk of birth of a child with DS (Table 2).
Particularly, ﬁve meta-analyses have been published between
2013 and 2014 to address this issue (Costa-Lima et al., 2013; Wu
et al., 2013; Yang et al., 2013; Rai et al., 2014; Victorino et al.,
2014), with the most recent including data from 34 case-control
studies for a total of 3.098 MDS and 4.852 control mothers (Rai
et al., 2014). They mainly diﬀer for the inclusion criteria because,
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according to the author’s mother language, not only papers
written in English, but also those written in Chinese or in Spanish
and Portuguese languages have been included. However, all those
meta-analyses agree that the overall odds ratio (OR) for the birth
of a child with DS in carriers of the 677T allele ranges from 1.2 to
1.5 according to the genetic model under investigation, i.e., allele
contrast, dominant, recessive, co-dominant, etc. (Table 2). The
ﬁrst meta-analysis in this ﬁeld also provided the ﬁrst attempt of
data stratiﬁcation into ethnic groups, and particularly the author
performed a subgroup analysis in Caucasians, called “whites” in
the original paper, including data from both European and North
American studies and observing no signiﬁcant contribution of
the polymorphism in this group (Zintzaras, 2007). Data in
populations from Asia, from the Middle East, or in mixed
Brazilians were scarce to perform subgroup stratiﬁcation at that
time (Zintzaras, 2007). Subsequent data stratiﬁcation into ethnic
groups revealed that the risk is higher in Asians (OR of about 1.5
or higher, depending on the studied genetic model), and lower in
Caucasians and/or other groups (OR usually ranging between 1.0
and 1.4) (Table 2). In those studies inhabitants of North America
and of the Middle East were included together with Europeans
in the Caucasian subgroup (Wu et al., 2013; Yang et al., 2013;
Victorino et al., 2014). For what concerns the studies performed
in Brazilian populations, all were performed in mixed Brazilian
populations, with the exception of one study (Brandalize et al.,
2009) that was performed in Brazilians of European descent,
but they were grouped together as “Brazilians” or “others” in
the meta-analyses (Wu et al., 2013; Yang et al., 2013; Victorino
et al., 2014) (Table 2). Those meta-analyses also revealed that the
frequency of theMTHFR 677T allele is higher in Caucasian MDS
(ranging from 35.6 to 41.5%), followed by Brazilians (ranging
from 33.5 to 33.9%), and lower in Asian populations (ranging
from 20.0 to 32.3%) (Wu et al., 2013; Victorino et al., 2014).
Moreover, when data were stratiﬁed according to the geographic
origin of the mothers, rather than ethnicity, the higher risk was
again observed in Asians (OR = 1.53; 95% CI = 1.29–1.82),
followed by Americans (OR = 1.23; 95% CI = 1.07–1.39), and
the result was not signiﬁcant in Europeans (OR= 1.04; 95% CI=
0.93–1.16) (Rai et al., 2014). In that study Brazilians and North
Americans were collectively subgrouped as Americans (Rai et al.,
2014). Similarly, data stratiﬁcation according to latitude, revealed
a signiﬁcant eﬀect of the MTHFR 677C>T polymorphism in
inhabitants of sub-tropical regions (both TT vs. CC and CT
vs. CC carriers), followed by tropical regions (only CT vs. CC
carriers), but no signiﬁcant eﬀect was observed for those living
in northern regions of the globe (Costa-Lima et al., 2013).
Those data reﬂect complex gene-environment interactions, and
are likely to be the result of diﬀerences in allele frequencies
among diﬀerent populations coupled with diﬀerent nutritional
habits and exposure to environmental factors, such as sun-
light radiations, that could interfere with folate bioavailability
(Martínez-Frías, 2008; Coppedè, 2009; Costa-Lima et al., 2013;
Rai et al., 2014).We should not forget that the eﬀect of themutant
MTHFR 677TT genotype is exacerbated under conditions of
low folate intake/bioavailability, but can be counteracted by
physiological levels of folate (Martínez-Frías, 2008). Collectively
those data reveal theMTHFR 677C>T polymorphism represents
a weak maternal risk factor for the birth of a child with DS,
particularly in those women subjected to nutritional and/or
environmental factors resulting in reduced folate bioavailability.
Interestingly, we observed association of the MTHFR 677C>T
polymorphism with both chromosome 13 and 21 malsegregation
events in lymphocytes of MDS and matched control mothers,
evaluated by means of the micronucleus assay coupled with
ﬂuorescence in situ hybridization (FISH) to detect aneuploidy
(Coppedè et al., 2007, 2009).
Another common MTHFR polymorphism, the MTHFR
1298A>C one (rs1801131), results in a Glu429Ala aminoacidic
change and is in linkage disequilibrium with the MTHFR
677C>T one. Particularly, the MTHFR 677T-1298C haplotype
is rare, and the double homozygous 677TT-1298CC genotype
leads to MTHFR protein instability and inactivity, often resulting
in prenatal death (Martínez-Frías, 2008). Meta-analysis data
revealed that the frequency of theMTHFR 1298C allele is higher
in Asians (36.0–40.0%), followed by Caucasians (33.0–35.0%)
and Brazilians (23.0–25.0%) (Victorino et al., 2014). All the
literature meta-analyses performed so far reveal that theMTHFR
1298A>C polymorphism is not an independent maternal risk
factor for the birth of a child with DS, even after subgroup
stratiﬁcation for ethnicity or geographical factors (Table 2).
However, several case-control studies revealed that haplotypes
or combined genotypes generated by MTHFR 677C>T and
1298A>C polymorphisms increase the maternal risk for a
birth of a child with trisomy 21 more than the presence of
the MTHFR 677C>T one alone, strengthening the evidence
of a functional interaction of both polymorphisms on protein
stability and activity (Grillo et al., 2002; Acácio et al., 2005;
Scala et al., 2006; Brandalize et al., 2009; Zampieri et al.,
2012b).
Methionine Synthase and Methionine Synthase
Reductase (MTR and MTRR)
MTR is a cobalamin-dependent enzyme that catalyzes the
transmethylation of hcy to methionine and MTRR, a NADPH-
dependent diﬂavin enzyme, is required for the reductive
activation of MTR (Figure 1). A common MTRR 66A>G
polymorphism (rs1801394), resulting in Ile22Met amino acid
change, was the second polymorphism of the folate pathway,
after the MTHFR 677C>T one, to be associated with the
maternal risk of having a birth with DS in North American
women (Hobbs et al., 2000). Subsequent research papers yielded
conﬂicting results (Table 1), but starting from the meta-analysis
conducted in 2009 by Medica and coworkers in 623 MDS and
936 control mothers (Medica et al., 2009), all the following
meta-analyses conﬁrmed association of this polymorphism with
maternal risk for trisomy 21 in the oﬀspring, with overall
ORs ranging from 1.2 to 1.6 depending on the genetic model
under investigation (Table 2). Subgroup stratiﬁcation into ethnic
groups, performed by recent meta-analyses (Balduino Victorino
et al., 2014; Coppedè et al., 2014), suggests a signiﬁcant eﬀect in
Caucasians under both dominant and recessive genetic models
(Table 2). Particularly, for this polymorphism the frequency
of the MTRR 66G allele ranges from 35.8 to 54.3% among
Caucasians, from 40.0 to 48.0% in mixed Brazilian populations,
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and from 41.5 to 62.5% in Asians (Wang et al., 2008; Balduino
Victorino et al., 2014; Coppedè et al., 2014). Furthermore,
geographic stratiﬁcation among Caucasians revealed that the risk
is higher in those of European descent that do not live in Europe
(OR = 1.47; 95% CI = 1.02–2.11; dominant model) than in
European Caucasians (OR= 1.31; 95%CI= 1.01–1.70; dominant
model). Furthermore, when the analysis was restricted to the
Caucasian inhabitants of Mediterranean regions no signiﬁcant
eﬀect was observed (OR = 1.19; 95% CI = 0.91–1.55; dominant
model), suggesting that also for this polymorphism geographic
and dietary factors can counteract the negative eﬀect of the
genetic background (Coppedè et al., 2014). Recently, another
MTRR polymorphism, namely MTRR 524C>T (rs1532268)
resulting in Ser175Leu replacement, has been linked to the
maternal risk of birth of a child with DS (Wang et al., 2013a).
Particularly, the authors observed decreased maternal risk for
carriers of the 524T allele that was associated with reduced hcy
levels in Chinese women, but did not search for linkage or
interaction with theMTRR 66A>G one (Wang et al., 2013a).
Concerning the MTR gene, the MTR 2756A>G
polymorphism (rs 1805087), leading to the Asp919Gly
substitution, was the third variant of the folate pathway to
be associated with the maternal risk of having a birth with DS
(Bosco et al., 2003). However, subsequent case-control studies
failed to conﬁrm this association (Table 1), and recent meta-
analyses conﬁrmed that the MTR 2756A>G polymorphism
is not an independent maternal risk factor for a DS oﬀspring
(Yang et al., 2013; Coppedè et al., 2013a; Balduino Victorino
et al., 2014). The contribution of the MTR 2756G allele to
the maternal risk of birth of a child with DS was investigated
mainly in European and mixed Brazilian populations, with
similar reported allele frequencies of about 18–21% (Coppedè
et al., 2013a), while the study by Liao et al. (2010) showed allele
frequencies of less than 10% in Asians. The functional role
of both MTR 2756A>G and MTRR 66A>G polymorphisms
has been largely investigated with regards to their possible
contribution to circulating hcy, folate, or vitamin B12 levels,
yielding conﬂicting results (Coppedè, 2009). In this regard, we
recently screened a large cohort of MDS and matched control
mothers observing that the MTRR 66A>G polymorphism, but
not theMTR 2756A>G one, was associated with increased serum
folate levels in GG carriers (Coppedè et al., 2013a, 2014). Others,
reported association of MTRR AG and GG genotypes with high
methylmalonic acid (MMA) concentrations, an indicator of
the vitamin B12 status, in Brazilian women (Zampieri et al.,
2012b). However, when both polymorphisms were considered
simultaneously, carriers of the combined MTR 2756AA/MTRR
66GG genotype showed increased serum folate levels, while
carriers of the MTR 2756GG/MTRR 66AA genotype had both
reduced folate and hcy levels (Coppedè et al., 2014). Several
previous papers reported joint eﬀects of polymorphisms of
genes of the folate metabolic pathway to circulating levels of
B vitamins, hcy or related metabolites, as well as to the overall
maternal risk of birth of a child with DS: for example, complex
interactions between MTRR 66A>G and MTHFR 1298A>C
polymorphisms signiﬁcantly aﬀected hcy levels in Spanish MDS
and control mothers (Martínez-Frías et al., 2006), and many
authors reported association of combined MTHFR/MTRR or
MTRR/MTR genotypes with maternal risk of birth of a DS
baby (Hobbs et al., 2000; Bosco et al., 2003; Wang et al., 2008;
Coppedè et al., 2009, 2014; Brandalize et al., 2010; Liao et al.,
2010) (Table 1).
Reduced Folate Carrier (RFC1)
The ubiquitously expressed RFC has unequivocally established
itself as the major transport system in mammalian cells and
tissues for folate cofactors (Hou andMatherly, 2014). A common
RFC1 80G>A polymorphism (rs1051266), resulting in Arg27His
replacement, was suggested to alter folate uptake, and the
combined RFC1 80GG/MTHFR 677TT genotype was associated
with increased plasma hcy levels (Chango et al., 2000). In 2006,
we observed a borderline signiﬁcant increased maternal risk of
birth of a child with DS for carriers of the combined RFC1
80GG/MTHFR 677TT genotype, and a reduced risk for carriers of
RFC1 80(AA or AG)/MTHFR 1298AA genotypes (Coppedè et al.,
2006). Subsequent studies evaluating the possible contribution
of this polymorphism to the maternal risk of having a DS child
were conﬂicting (Table 1), but two recent meta-analyses (Yang
et al., 2013; Coppedè et al., 2013c) suggest that it could represent
an independent maternal DS risk factor with ORs ranging from
1.1 to 1.3 according to the model under investigation (Table 2).
Moreover, despite that its functional role is still controversial,
the RFC1 80G>A polymorphism has been associated with
reduced red cell folate concentrations among healthy women
(Stanisławska-Sachadyn et al., 2009), and with reduced serum
folate concentrations in MDS (Zampieri et al., 2012b). However,
less than 1.000 MDS were available for those meta-analyses,
and subgroup stratiﬁcation yielded inconclusive results likely
because of the small case-control cohorts in each ethnic group
(Coppedè et al., 2013c; Yang et al., 2013). However, RFC1 80G
allele frequency resulted higher in Caucasian and Brazilian MDS
(ranging between 49.0% and 54.0%) than in Asian ones (36.0–
36.5%) (Coppedè et al., 2013a). Therefore, further studies are
required to clarify the contribution of this polymorphism to the
maternal risk of a DS birth.
Cystathionine β-synthase (CBS)
CBS is a hemoprotein that catalyzes the condensation of
hcy and serine to form cystathionine in the transsulfuration
pathway (Figure 1). Concerning the CBS gene, two common
polymorphisms have been investigated as maternal risk factors
for the birth of a child with DS (Table 1). The ﬁrst one consists
of the insertion of 68-bp within exon 8 (CBS 844ins68, no
rs#) that results in the duplication of a splice site at the
intron7/exon 8 junction of the gene (Sperandeo et al., 1996),
and two recent literature meta-analyses, both performed with
825 MDS and 1.034 control mothers, failed to ﬁnd association
of the CBS 844ins68 allele and maternal risk of having a DS
child (Yang et al., 2013; Balduino Victorino et al., 2014). The
second polymorphism, an 833T>C substitution (rs5742905)
leading to an Ile278Thr replacement associated with mild
hyperhomocysteinemia (Shao et al., 2005), gave conﬂicting
results as a maternal risk factor for a DS birth in genetic
association studies (Zampieri et al., 2012b; Wang et al., 2013b),
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but has been investigated less extensively than the previous one
and no meta-analysis is yet available.
Methylenetetrahydrofolate Dehydrogenase
(MTHFD1)
MTHFD1 is a trifunctional enzyme of pivotal importance
in the interconversion of folate cofactors for either nucleic
acid synthesis or hcy remethylation reactions (Figure 1). The
MTHFD1 1958G>A polymorphism (rs2236225), leading to
Arg653Gln, reduces enzyme stability and activity and was ﬁrst
investigated as a maternal risk factor for trisomy 21 in Southern
Italian women, showing association with DS risk in combination
with the RFC1 80G>A polymorphism (the combined MTHFD1
1958AA/RFC1 80GG genotype) (Scala et al., 2006). Subsequent
studies were conﬂicting (Zampieri et al., 2012a,b; Liao et al.,
2014; Izci Ay et al., 2015), but a recent meta-analysis of 497
MDS and 930 control mothers revealed a weak association with
maternal risk of DS, but only in GA vs. GG carriers (OR =
1.33; 95% CI = 1.01–1.75) (Balduino Victorino et al., 2014).
This is a very interesting data, but results are still preliminary
due to the relatively small number of MDS available for the
meta-analysis. Indeed, subgroup stratiﬁcation was not possible
(Balduino Victorino et al., 2014), making this variant a candidate
allele to be investigated in further studies.
Transcobalamin (TCN2)
In the circulation, TC is the transport protein of cobalamin
required for its cellular uptake mediated by speciﬁc membrane
receptors (TCR) (Figure 1). A common TCN2 776C>G
polymorphism (rs1801198), results in Arg232Pro replacement
and impairs cobalaminmetabolism (von Castel-Dunwoody et al.,
2005). Genetic association studies revealed associations of this
polymorphism with maternal risk of DS birth either alone
(Zampieri et al., 2012b), or in combination withMTR (combined
TCN2 776CC/MTR 2756AG genotype) (Fintelman-Rodrigues
et al., 2009) or MTHFR (combined TCN2 776CG/MTHFR
677TT genotype) (Liao et al., 2014) polymorphisms. However,
a recent meta-analysis of 495 MDS and 743 control mothers
failed to conﬁrm it as independent maternal risk factor for the
birth of a DS baby (Balduino Victorino et al., 2014). Another
TCN2 polymorphism, TCN2 67A>G (rs9606756) leading to
Ile23Val substitution, was investigated only in Brazilian women
and showed no association with maternal risk for a DS birth
(Zampieri et al., 2012b).
Serine-Hydroxymethyltransferase (SHMT),
Thymidilate Synthase (TYMS), and Dihydrofolate
Reductase (DHFR)
SHMT uses serine as the one-carbon donor for the conversion of
THF into 5,10-methyleneTHF, that can be used for thymidylate
synthesis in the reaction catalyzed by TYMS that produces
dTMP and DHF, which is then reduced back to THF by DHFR
(Figure 1). Polymorphisms of SHMT, TYMS, and DHFR have
been investigated only in one case-control study each (Coppedè
et al., 2009; Mendes et al., 2010; Marucci et al., 2012) so that
data are still preliminary and no meta-analysis is yet possible.
Particularly, the SHMT 1420C>T polymorphism (rs1979277),
that results in Leu474Phe replacement and impairs SHMT
nuclear transport and subsequent thymidilate synthesis (Woeller
et al., 2007), was investigated in 105 MDS and 185 control
mothers from Brazil, and both 1420CC (OR = 0.35; 95% CI =
0.2–0.6) and 1420CT (OR = 0.2; 95% CI = 0.1–0.4) genotypes
resulted in a decreased maternal risk of birth of a child with
DS with respect to the 1420TT genotype (Marucci et al., 2012).
We investigated two common TYMS polymorphisms in 94
MDS and 113 control mothers of Italian origin (Coppedè et al.,
2009), namely a 28-bp short tandem repeats (rs34743033) in the
5′-untranslated region (5′-UTR) that is linked to gene expression
levels (Horie et al., 1995), and a 6-bp deletion (1494 ins/del)
polymorphism in the 3′-UTR (rs34489327) that aﬀects mRNA
stability into the cytoplasm (Ulrich et al., 2002). None of the
two studied TYMS polymorphisms resulted an independent
maternal risk factor for a DS birth, but the combined MTHFR
1298AC/TYMS 28-bp 2R/2R genotype resulted in decreased
maternal risk (Coppedè et al., 2009). Concerning the DHFR
gene, Mendes and coworkers (2010) genotyped 105 MDS and
185 control mothers from Brazil for the presence of a 19-bp
ins/del polymorphism (rs70991108) that was previously linked
to alterations in folate metabolism (Kalmbach et al., 2008), but
no association with maternal risk of a DS birth was observed
(Mendes et al., 2010). Unfortunately, due to the absence of
replication studies, none of these polymorphisms can be
conﬁrmed or excluded as a maternal risk factor for having a birth
with trisomy 21.
Betaine-homocysteine Methyltransferase
(BHMT)
BHMT is a zinc-dependent protein that catalyzes the synthesis of
methionine from the methyl-donor betaine and hcy (Figure 1),
thus contributing to the regulation of homocysteine levels, and
is particularly active in the liver and in the kidneys (Obeid,
2013). A BHMT 742G>A polymorphism (rs3733890) leads to
Arg239Gln substitution and to a slight reduction in enzyme
kinetics, that however do not appear to alter circulating hcy
levels (Li et al., 2008). However, three recent case-control studies
performed in Brazilian women (Zampieri et al., 2012a,b; Amorim
et al., 2013) suggest that carriers of the BMTH 742A allele,
and particularly homozygous 742AA carriers, are at decreased
maternal risk of birth of a child with DS than 742GG carriers
(Table 1), making this gene a valuable candidate for further
investigation.
DNA Methyltransferase 3B (DNMT3B)
In their pioneering studies James et al. (1999) and Hobbs
et al. (2000) advanced the hypothesis that polymorphisms
of folate pathway genes could result in altered methylation
of chromosome 21 peri-centromeric regions, favoring its
malsegregation during maternal meiosis. Particularly, to
support a causal association between DNA hypomethylation,
peri-centromeric decondensation, and abnormal chromosome
segregation, Hobbs et al. (2000) reported the example of the
monogenic disease, Immunodeﬁciency, Centromeric instability
and Facial anomalies (ICF) syndrome, which is a Mendelian
disorder associated with DNMT3B mutations and DNA
methylation defects of satellite and non-satellite regions (Hobbs
et al., 2000). Despite that a direct evidence of a link between
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folate pathway gene polymorphisms and DNAmethylation levels
of chromosome 21 peri-centromeric regions has not yet been
demonstrated, two recent genetic association studies suggest
that promoter polymorphisms of the DNMT3B gene might be
associated with the maternal risk of birth of a child with DS
(Coppedè et al., 2013b; Jaiswal et al., 2015). DNMT3b is a de novo
DNMT that localizes primarily to the nucleus, and is required
for the regulation of DNA methylation at centromeric and peri-
centromeric regions of human chromosomes (Gopalakrishnan
et al., 2009). DNMT3B promoter polymorphisms, namely
-149C>T (rs2424913) and -579G>T (rs1569686), are in strong
linkage disequilibrium, give rise to functional haplotypes that
could impair protein expression levels, and have been associated
to various kinds of human cancers (Zhu et al., 2012). We
genotyped 172 MDS and 157 control mothers of Italian origin
observing a decreased risk of birth of a child with DS in carriers
of the DNMT3B -579T allele, with respect to GG carriers;
moreover, the combined DNMT3B -579GT/-149CC genotype
was associated with an even more signiﬁcant reduced maternal
risk of birth of a child with DS (Table 1) (Coppedè et al., 2013b).
More recently, a similar study performed in 150 IndianMDS and
172 control mothers revealed a signiﬁcant increased frequency of
the DNMT3B -579G/-149T haplotype in the MDS group (Jaiswal
et al., 2015). Overall, both studies suggest that combinations of
DNMT3B promoter polymorphisms might be associated to the
maternal risk for having a birth with trisomy 21, however data
are still preliminary and should be conﬁrmed in future studies.
Gene-gene Interactions
Table 1 clearly shows that many authors reported an increased
maternal risk of birth of a child with DS for carriers of combined
genotypes given by the presence of two simultaneous risk alleles,
mainly combinations of MTHFR 677T and 1298C alleles, or
combinations of MTHFR 677T and MTRR 66G ones (Table 1).
However, when authors searched for the simultaneous presence
of more than two risk alleles, they often reported increased
maternal risk for a DS birth with the increasing number of
variants in folate pathway genes carried by the mother: for
example, da Silva et al. (2005) observed that MDS tend to
presentmore variant alleles than controlmothers amongMTHFR
677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G,
and CBS 844ins68 polymorphisms, and the presence of each
uncommon allele was associated with an increment of 25.9%
in the risk of a DS pregnancy (da Silva et al., 2005). Similarly,
Biselli et al. (2008b) observed that the presence of three or more
variant alleles among MTHFR 677C>T, MTHFR 1298A>C,
MTR 2756A>G, and RFC1 80G>A, resulted in a 1.7-fold
increase inmaternal risk for a DS birth (Biselli et al., 2008b), while
Brandalize et al. (2010) analyzed the genotypes generated by
the following polymorphisms: MTR 2756A>G, MTRR 66A>G,
CBS 844ins68, and RFC1 80G>A, observing that the OR for
having a child with DS ranged from 4.8 to 6.9 depending on
the number of risk genotypes considered (Brandalize et al.,
2010). We used artiﬁcial neural networks (ANNs) to discriminate
between MDS and control mothers using genotyping data and
the frequency of chromosome damage and malsegregation in
peripheral lymphocytes evaluated by means of the micronucleus
assay (Coppedè et al., 2010). ANNs revealed that micronucleus
frequency and genotyping data for MTHFR 677C>T, TYMS
28bp repeats, TYMS 1494 6bp ins/del, MTR 2756A>G, and
RFC1 80G>A polymorphisms, allowed to discriminate between
MDS and control mothers with 90% accuracy (Coppedè et al.,
2010). Overall, those data suggest that the combined presence of
several variant alleles of folate pathway genes is likely to increase
signiﬁcantly the maternal risk of birth of a child with DS.
Gene-nutrient Interactions
In their pioneering study James et al. (1999) not only observed
an increased frequency ofMTHFR 677CT and TT genotypes, but
also increased hcy levels, and association of those genotypes with
increased hcy levels in MDS with respect to control mothers.
Furthermore, the authors noticed an impaired hcy/methionine
ratio in MDS, and estimated from food questionnaires that MDS
had lower folate intake than the recommended daily allowance
at the time of conception (James et al., 1999). In addition,
alcohol intake estimated from the questionnaires, which is known
to impair MTR activity and hcy to methionine conversion,
was higher in MDS than in control mothers (James et al.,
1999). Overall, the authors suggested complex gene-environment
interactions at the basis of thematernal susceptibility for the birth
of a child with DS, and many others have subsequently measured
or estimated biomarkers of one-carbon metabolism in MDS and
control mothers, including plasma hcy, plasma or serum folate,
vitamin B6 and/or vitamin B12, red blood cell (RBC) folate, and
related micronutrients, searching for association with the genetic
polymorphisms of folate pathway genes (Table 3). Despite that
those studies are often conﬂicting, most of them reported
increased hcy levels or decreased measured or estimated folates
in MDS with respect to control mothers (Table 3), and several
authors observed association with the studied polymorphisms,
including MTHFR 677C>T and 1298A>C polymorphisms that
were often associated with increased hcy levels (James et al.,
1999; O’Leary et al., 2002; da Silva et al., 2005; Martínez-Frías
et al., 2006; Wang et al., 2007; Biselli et al., 2008b; Zampieri
et al., 2012b). Similarly, the MTRR 66A>G polymorphism was
linked to MMA levels, an indicator of the vitamin B12 status
(Zampieri et al., 2012b), with hcy levels in interaction with
the MTHFR 1298A>C polymorphism (Martínez-Frías et al.,
2006), and with both folate and hcy levels in combination with
the MTR 2756A>G one (Coppedè et al., 2014). The MTRR
524C>T polymorphism was associated with reduced hcy levels
in carriers of the MTRR 524TT genotype (Wang et al., 2013a),
and the RFC1 80GG genotype was associated with high plasma
folate levels in women aged 35 years or less at conception
(Zampieri et al., 2012b). In summary, all the three genetic
polymorphisms (MTHFR 677C>T, MTRR 66A>G, and RFC1
80G>A) which have been linked to the maternal risk for the
birth of a child with DS by literature meta-analyses (Table 2),
and other polymorphisms in the same genes (MTHFR 1298A>C
andMTRR 524C>T), have been associated with hematochemical
markers of one-carbon metabolism (Table 3). Limitations of
those studies, that could also partially account for the conﬂicting
nature of the ﬁndings, include the fact that in most of the
cases the hematochemical markers have been measured after
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the birth of DS or healthy children, and do not represent the
nutritional status at the time of peri-conception (reviewed in
Coppedè, 2009). In this regard, some authors made attempts
to estimate the nutritional status at peri-conception by means
of food questionnaires (James et al., 1999; Kohli et al., 2008;
Meguid et al., 2008; Santos-Rebouças et al., 2008) and others
evaluated RBC folate levels that are more useful to monitor the
long-term folate status, with respect to serum or plasma folate
levels that are only indicators of recent folate intake (Mohanty
et al., 2012; Pandey et al., 2013). Data on alcohol consumption
at peri-conception are however scarce from those studies (James
et al., 1999), and this is another factor that could interfere with
one-carbonmetabolism, as well as smoking habits or information
on other micronutrients, such as for example zinc which may
aﬀect the activities of enzymes such as BHMT and MTR (Santos-
Rebouças et al., 2008; Fenech, 2012). Taken overall, the studies
listed in Table 3 suggest that certain polymorphisms in folate
pathway genes are associated with the levels of hematochemical
markers of one-carbon metabolism, and that certain MDS could
have been under conditions of folate restriction and/or increased
hcy levels at the time of conception. However, the complex
link between the risk of birth of a child with DS and the
intake of dietary folate and related vitamins and micronutrients
at peri-conception could be clariﬁed only by future and well-
designed prospective studies on large cohorts of individuals.
In this regard, it will be also of fundamental importance to
take into account that the nutritional status and requirements
of three diﬀerent generations (Figure 2), namely the maternal
grandmother, the mother, and the developing DS embryo,
coupled with the presence of polymorphisms of folate pathway
genes, with the exposure to factors such as alcohol drinking and
cigarette smoking during pregnancy, and with the nature of the
meiotic error leading to chromosome 21 malsegregation, could
interact to determine not only the formation of an embryo with
trisomy 21, but also which DS embryo will survive up to the birth
(Martínez-Frías et al., 2006; Coppedè, 2009).
Unfortunately, none of the available meta-analyses listed in
Table 2 made subgroup comparison between countries with
and without mandatory folic acid fortiﬁcation of foods. Since
1998, fortiﬁcation of grain products with folic acid has been
mandated in the United States of America and subsequent studies
revealed that this resulted in changes in the birth prevalence
of neural tube defects (NTDs), with modest or no eﬀect in
reducing the birth prevalence of DS individuals (Simmons et al.,
2004; Canﬁeld et al., 2005), and similar results were observed
in other countries after fortifying wheat ﬂour with folic acid
(Castilla et al., 2003; Goh et al., 2006). Unfortunately, the two
available North American studies addressing the contribution
of MTHFR 677C>T and/or MTRR 66A>G polymorphisms to
the maternal risk for having a child with DS were published
in 1999 and 2000 (James et al., 1999; Hobbs et al., 2000) and
therefore, despite that both observed signiﬁcant associations
between the studied polymorphisms and maternal risk for DS,
women enrolled in those studies were mainly collected from 1989
to 1998 and are unlikely to have beneﬁted from the fortiﬁcation
(Hobbs et al., 2000). However, as discussed in Section “The
Biology of Human Female Meiosis, the Origin of Chromosome
21 Malsegregation, and the Potential Contribution of Dietary
Folate Availability,” a recent case-control study conducted by
Hollis and coworkers at six recruitment sites in the United
States from 2000 through 2004 (Hollis et al., 2013) revealed
that lack of folic acid fortiﬁcation at peri-conception resulted
in increased risk for DS cases due to maternal MII errors in
women older than 35 years. Unfortunately, the contribution
of folate pathway gene polymorphisms was not evaluated in
that study (Hollis et al., 2013). Brazil is another country with
mandatory folic acid fortiﬁcation since 2004, but recent meta-
analyses revealed a signiﬁcant contribution of the MTHFR 677T
allele as maternal risk factor for the birth of a child with DS in
Brazilian women (Yang et al., 2013; Victorino et al., 2014). By
contrast, the fortiﬁcation is not mandatory in Europe and inmost
Asian countries (Choi et al., 2014). However, taking into account
the possible contribution of the maternal grandmother’s diet to
the maternal risk of birth of a child with DS (Figure 2), it is
likely that a better comprehension of the eﬀect of the mandatory
fortiﬁcation adopted by several countries will be possible only in
the next generations.
Maternal Polymorphisms of Folate
Pathway Genes and Risk of Congenital
Heart Defects in the DS Child
Several congenital complications are observed in individuals
with DS (for a review see Weijerman and de Winter, 2010),
some of which potentially aﬀected by impaired maternal one-
carbon metabolism and consequent epigenetic changes during
embryogenesis or impaired requirements of DNA precursors for
cellular divisions. However, in this review article the author will
focus on congenital heart defects, due to an increasing evidence
of a possible contribution of polymorphisms in folate-pathway
genes to their occurrence in the DS oﬀspring (Table 4) coupled
with scarce or absence of data for other DS comorbidities. The
prevalence of CHD in neonates with DS ranges from 43 to
58% worldwide, with atrioventricular septal defect (AVSD) and
ventricular septal defect (VSD) being the most common forms
of all CHD in children with DS (Weijerman and de Winter,
2010). Quite recently, a population-based case-control study,
which included 1.011MDS that reported their use of supplements
containing folic acid at peri-conception, showed that lack of
maternal folic acid supplementation was more frequent among
infants with DS and AVSD (OR = 1.69; 95% CI = 1.08–2.63)
or atrial septal defects (OR = 1.69; 95% CI = 1.11–2.58) than
among infants with DS and no heart defect, suggesting that lack
of maternal folic acid supplementation is associated with septal
defects in infants with DS (Bean et al., 2011). Unfortunately,
only a few case-control studies have been conducted so far to
evaluate polymorphisms in folate-pathway genes as risk factors
for CHD occurrence in a DS birth (listed in Table 4), and
no meta-analysis of the data is yet possible. Brandalize et al.
(2009) genotyped 239 Brazilian MDS for MTHFR 677C>T and
1298A>C polymorphisms, including 90 mothers of a DS child
with CHD (DS-CHD) and 149 mothers of a DS child without
CHD. The authors observed that MDS carriers of the MTHFR
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677CT or TT genotype had an increased risk for DS-CHD in
the oﬀspring (OR = 2.07; 95% CI = 1.18–3.61). However, when
MDS were stratiﬁed according to folic acid supplementation at
peri-conception, the risk for DS-CHD remained signiﬁcant only
in those with MTHFR 677CT or TT genotype that did not take
folic acid supplements (OR = 2.26; 95% CI = 1.25–4.09), but
was lost in those MDS that used folic acid supplements at peri-
conception (OR = 1.07; 95% CI = 0.20–5.68). No association
with DS-CHD risk was observed for the MTHFR 1298A>C
polymorphism (Brandalize et al., 2009). Locke et al. performed
a case-control study in a group of 121 American case families
(mother, father, and proband with DS and AVSD) and 122
American control families (mother, father, and proband with
DS and no CHD), all genotyped for 45 polymorphisms in
MTHFR, MTR, MTRR, RFC1, and CBS genes, observing that
several RFC1 polymorphisms, all in strong linkage with the
RFC1 80G>A one, showed nominally signiﬁcant associations
with AVSD, with ORs of between 1.34 and 3.78. In addition,
theMTHFR 1298A allele was over-transmitted to DS individuals
with AVSD and under-transmitted to those with no CHD (Locke
et al., 2010). By contrast, Božovic´ et al. (2011) genotyped 112 DS
subjects (54 with CHD and 58 without CHD) and 221 matched
controls from Croatia for both MTHFR 677C>T and 1298A>C
polymorphisms, observing no diﬀerence in allele or genotype
frequencies for both polymorphisms between DS-CHD cases and
DS cases without CHD, or between DS cases and healthy controls
(Božovic´ et al., 2011). Furthermore, the authors genotyped 107
MDS and 34 complete parent–oﬀspring triads. No association
was observed between the presence of eitherMTHFR 677C>T or
MTHFR 1298A>C polymorphism in the mother and risk of DS-
CHD oﬀspring, and all MDS did not use folic acid supplements
at peri-conception; similarly, the allele transmission of the two
MTHFR polymorphisms showed no deviations from random
segregation, leading the authors to conclude that none of the
studied polymorphisms was associated with CHD risk in their
cohort (Božovic´ et al., 2011). More recently, Elsayed et al. (2014)
genotyped 61 Egyptian mothers of children with septal defects
(25 with DS and 36 without DS) and 61 control mothers (with
no children with DS or CHD) who did not receive folic acid
supplementation in the peri-conceptional period. All women
were genotyped for theMTHFR 677C>T polymorphism, and the
MTHFR 677CT genotype resulted signiﬁcantly higher in mothers
of DS with atrioventricular (AV) canal compared to control
mothers (OR: 1.21, 95%CI: 1.02–1.43). Collectively those papers
are conﬂicting but four out of ﬁve of them (Brandalize et al., 2009;
Locke et al., 2010; Bean et al., 2011; Elsayed et al., 2014) suggest a
possible contribution of folate metabolism to the development of
CHD in DS individuals.
Despite that a meta-analysis of the few studies of DS-CHD is
yet not possible due to their relatively small number (Table 4),
a recent meta-analysis of 18 case-control studies, that included
data from 18.500 cases of CHD, revealed that maternal folic acid
supplementation is associated with a signiﬁcant decreased risk of
CHD (OR: 0.72, 95%CI: 0.63–0.82), and the association remained
signiﬁcant even after stratiﬁcation of the data into CHD subtypes
(Feng et al., 2015). Similarly, recent literature meta-analyses of
non DS-CHD cases revealed association of maternal MTHFR
677C>T and MTRR 66A>G polymorphisms with CHD risk
in the oﬀspring (Wang et al., 2013c; Cai et al., 2014), leading
authors to hypothesize that methylation proﬁles and other
epigenetic abnormalities could contribute to the etiology of heart
malformations.
In this regard, Obermann-Borst et al. (2011) performed a
study in 143 Dutch children with CHD and 186 healthy children,
observing that in the overall CHD group, blood SAM levels,
serum folate, and RBC folate levels were signiﬁcantly higher than
in the controls. However, when the analysis was restricted to the
subgroup of children with DS-CHD, they showed signiﬁcantly
lower SAM:SAH ratio (the DNA methylation potential) than
other CHD cases, suggesting that cases of DS-CHD may be
associated with global hypomethylation (Obermann-Borst et al.,
2011). A recent study was performed to explore the global
methylation proﬁle of fetal heart DNA from 22 medically
terminated pregnancies (4 with normal development, 6 with
DS-CHD, 6 with DS without CHD, and 6 with isolated CHD)
in comparison to blood DNA from 656 subjects (Serra-Juhé
et al., 2015). The study revealed remarkably diﬀerent proﬁles
between tissues, with 407 genes hypomethylated in heart tissue
compared to blood, and 339 genes hypomethylated in blood
compared to heart tissue. Among the 22 heart DNA samples
signiﬁcant diﬀerences in DNA methylation proﬁles were seen
between fetuses with DS and fetuses with a normal karyotype.
The comparison of individual DS-CHD cases with two control
groups (normal development and DS without CHD) revealed
19 diﬀerentially methylated regions. Several epimutations were
detected in candidate genes involved in growth regulation,
apoptosis and folate pathway in cases of syndromic and isolated
CHD, providing evidence that impaired DNA methylation
occurred in their developing heart tissue, likely contributing to
the onset of CHD (Serra-Juhé et al., 2015).
Discussion and Conclusions
Despite that DS occurs in almost 1 on 700 live births, the
molecular mechanisms leading to maternal chromosome 21
malsegregation during oogenesis are still not fully understood.
Since 1999, it was suggested that maternal polymorphisms
in folate pathway genes could contribute to the epigenetic
regulation of the chromatin structure in those regions, thus
acting as maternal risk factors for the birth of a child with DS
(James et al., 1999). That hypothesis stimulated considerable
research over the last 15 years, leading to the production of more
than 50 case-control studies that, despite the conﬂicting nature
of their results, revealed a complexity of gene-gene and gene-
nutrient interactions in folate metabolism as potential maternal
risk factors for having a birth with trisomy for chromosome
21 (Table 1). More recent meta-analyses of those studies have
revealed that at least three of the most frequently studied
polymorphisms, namely MTHFR 677C>T, MTRR 66A>G, and
RFC1 80G>A, could act as weak independent maternal risk
factors for having a child with DS, with slight diﬀerences among
populations likely due to the existence of complex gene-gene and
gene-environment interactions (Table 2). Limitations of those
studies lies mainly in the fact that, with the exception of the
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most frequently studied MTHFR 677C>T polymorphism for
which data on over 3.000 MDS and almost 5.000 control mothers
were available for meta-analysis (Rai et al., 2014), data on all
the other polymorphisms are available for less than 2.000 MDS,
and often less than 1.000 MDS, limiting the power to detect
association also during meta-analysis (Table 2). Furthermore,
data concerning the occurrence of the meiotic error (MI or
MII), the maternal age at conception, as well as smoking and
drinking habits, are often unavailable in case-control studies,
making it impossible to evaluate their contribution during
the meta-analysis (Table 2). However, taking collectively the
literature produced so far in this ﬁeld, we can argue that there
is substantial evidence indicating that maternal impairments in
folate metabolism could favor at least certain errors leading to
chromosome 21 malsegragation; but considering that maternal
meiosis in a female starts during embryogenesis, the contribution
of the maternal grandmother’s folate intake is still a matter of
debate (Coppedè, 2009).
Furthermore, overexpression of folate pathway genes
mapping to chromosome 21 in a developing DS embryo could
result in a diﬀerent requirement of dietary folates with respect to
a normal embryo and, if not properly provided by the maternal
diet, could contribute to death in utero, impaired growth and, if
the birth is reached, to epigenetic changes of several genes likely
contributing to the onset of either congenital defects or other
diseases in adult-life (Martínez-Frías et al., 2006). Unfortunately,
our understanding of this is still in its infancy, due to scarce
availability of comparison data between women who experience
loss of trisomy 21 pregnancies and those with trisomic fetuses
that survive up to the birth, as well as to a few epigenetic studies
in DS individuals. In this regard, evidence is accumulating
concerning the possible contribution of impaired maternal
folate metabolism and epigenetic changes during embryogenesis
to the occurrence of DS-CHD cases (Table 4). We cannot
exclude that similar mechanisms could also account for other DS
comorbidities, but data are still scarce or missing. For example,
Brandalize et al. (2009) investigated whether or not maternal
MTHFR polymorphisms could account also for the occurrence
of congenital gastrointestinal disease in DS births observing
no association (Table 4), but they only had 16 DS cases with
gastrointestinal disease in their cohort (Brandalize et al., 2009).
Similarly, recent studies in DS individuals suggest that epigenetic
deregulation of several genes could not only account for CHD
(Serra-Juhé et al., 2015), but also for other complications such as
learning and memory deﬁcits (Dekker et al., 2014) or accelerated
aging (Horvath et al., 2015), but how much of this results from
in utero exposure is still unclear.
In conclusion, the available literature in this ﬁeld suggests that
it is now time for the design of large-scale prospective studies,
spanning over at least three diﬀerent generations, in order to
clarify the possible contribution of both maternal and maternal
grandmother’s diet and genotype to the occurrence of meiotic
errors favoring chromosome 21 malsegregation and the birth of a
DS child, as well as to other metabolic changes and/or epigenetic
modiﬁcations leading to death in utero or to the occurrence of
either congenital or age-related DS comorbidities.
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